This bill creates a formal Medicare pathway for devices the Secretary designates as “breakthrough.” It adds a new statutory designation, requires CMS to accept designation applications (with an 18‑month delay after enactment), and—if designated—automatically makes the device eligible for Medicare coverage for a four‑year “transitional” window when used consistent with FDA labeling and absent an undue risk determination.
The measure also imposes deadlines (a six‑month clock for designation decisions and stricter timing for national coverage determinations), requires annual reporting, authorizes reviews of aberrant billing for breakthrough devices, and provides $10 million per year to CMS for fiscal years 2025–2030. For manufacturers, hospitals, and Medicare administrators, the bill shifts how and when new technologies become payable under Parts A and B and raises practical questions about evidence thresholds, utilization, and fiscal exposure.
At a Glance
What It Does
Creates a new statutory category—‘breakthrough device’—and guarantees Medicare coverage for such devices during a four‑year transitional period when they are furnished according to FDA labeling and do not present undue risk. It requires CMS to decide designation applications within six months and speeds up final national coverage determinations for these devices.
Who It Affects
Device manufacturers seeking faster market access, hospitals and outpatient providers billing Medicare fee‑for‑service for device procedures, and CMS (which must process designations, NCDs, reports, and billing reviews). The provisions directly reference Parts A and B coverage; the bill does not explicitly alter Medicare Advantage rules.
Why It Matters
This is a structural change to the Medicare-device pathway: it moves coverage timing closer to FDA action and creates a predictable, time‑limited coverage window that can accelerate patient access but also exposes Medicare to earlier reimbursement decisions based on more limited evidence.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new statutory route for medically significant devices by defining a ‘‘breakthrough device’’ and attaching a four‑year Medicare coverage clock to that designation. A manufacturer may apply to the Secretary for the designation; if CMS approves, the device becomes eligible for Medicare payment for four years beginning on the designation date.
Coverage during that period is conditioned on the device being furnished in line with FDA‑approved labeling and on CMS not finding that clinical data show an undue risk that outweighs benefits.
CMS must start accepting applications 18 months after the law is enacted. The agency has a six‑month deadline to decide whether to grant designation once a manufacturer applies.
The statute ties the designation standard to FDA processes: priority review under FDA’s 515B program is an explicit criterion, and for devices cleared through 510(k) the bill requires that clearance relied on clinical data that included Medicare‑eligible individuals.To prevent these transitional cases from lingering, the bill tightens the timetable for national coverage determinations (NCDs): if a request for an NCD is filed within the windows specified (generally at least nine months before the end of the four‑year period, with a 12‑month variation in one circumstance), CMS must issue a final decision before the transitional period ends. The law also requires annual reporting to Congress on applications, designations, and denials, and it authorizes CMS to review providers with aberrant billing patterns for breakthrough devices.Finally, the statute supplies targeted administrative funding—$10 million per year, fiscal 2025–2030—to the CMS Program Management Account to stand up these processes.
Taken together, the bill moves device coverage decisions earlier in the commercialization pathway and builds in monitoring and enforcement levers to guard against misuse or unexpected harms.
The Five Things You Need to Know
The bill creates a new statutory category—‘breakthrough device’—and defines a four‑year “transitional coverage period” that begins on the date CMS designates the device.
CMS must begin accepting designation applications 18 months after enactment and decide each application within six months of submission.
Designation criteria require that the device received FDA priority review under section 515B and, for 510(k) clearances, that the clearance relied on clinical data including individuals covered by Medicare Parts A or B.
If an NCD request for a breakthrough device is submitted within specified pre‑end‑of‑period windows (generally 9 months, or 12 months in one case), CMS must issue a final NCD or determine coverage before the four‑year transition ends.
Congress appropriates $10 million annually (FY2025–FY2030, available until expended) to CMS’s Program Management Account to implement designation, NCD processing, reporting, and billing reviews.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creates a statutory coverage exception tied to the transitional window
The bill adds a new subparagraph to the Medicare payment exclusions provision to carve out breakthrough devices during their transitional coverage period. Practically, this means Medicare will not deny payment for a designated breakthrough device simply because it might otherwise be excluded under 1862(a)(1), provided the device is furnished per FDA labeling and CMS has not determined the clinical data show undue risk. That language preserves CMS’s ability to deny payment when a device is used off‑label or is shown to be unsafe.
Defines ‘breakthrough device’ and the four‑year transition
The bill adds a statutory definition that ties the breakthrough label to a separate designation (section 1899D) and makes the coverage trigger frequency‑based: devices are covered at the frequency in FDA labeling (or at CMS’s determined frequency if labeling is silent). It also sets the transitional coverage period at four years from designation — a clear, predictable window for manufacturers and providers to plan reimbursement and evidence‑generation activities.
Establishes application standards, timelines, and reporting for designation
This new section lays out who can apply (manufacturers of devices cleared, classified, or approved on or after the enactment date), the substantive criteria for designation (including FDA priority review and evidence requirements for 510(k) clearances), and a six‑month decision deadline. It requires CMS to explain denials with the specific criterion missed, mandates annual reports to Congress on application and designation counts, and authorizes CMS to investigate providers with aberrant billing for breakthrough devices.
Speeds national coverage determinations tied to transition timing
The bill amends NCD timing rules so that for breakthrough devices CMS must finalize an NCD (or otherwise recognize coverage) before the end of the device’s transitional period if the NCD request was filed within specified pre‑end windows. That creates a procedural backstop to ensure coverage questions are resolved before the automatic four‑year window expires, preventing a gap where devices could lose coverage unexpectedly.
Targeted CMS appropriations for implementation
The bill provides $10 million per year (FY2025–FY2030) to the CMS Program Management Account, available until expended. That money is intended to support the additional workload: processing designations, handling accelerated NCD timetables, producing annual reports, and conducting billing reviews. On paper the amount is modest given potential increases in claims volume and oversight needs.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare fee‑for‑service beneficiaries needing timely access — the four‑year window reduces the gap between FDA milestones and coverage, increasing earlier access to promising technologies for qualified patients.
- Device manufacturers pursuing faster commercial uptake — designation offers predictable, time‑limited coverage that can reduce reimbursement uncertainty and improve market access planning.
- Hospitals and clinicians that provide device procedures — the statutory coverage window and labeling‑based frequency reduce immediate billing ambiguity for commonly used breakthrough devices.
- CMS and Congress — the law builds in reporting and aberrant‑billing review powers that improve visibility into uptake, safety signals, and cost trajectory of new devices.
Who Bears the Cost
- Traditional Medicare (Parts A and B) financing — earlier coverage of novel devices will likely increase utilization and spending pressure on the trust funds absent offsets or utilization controls.
- CMS administration — the agency must stand up a new designation process, meet six‑month decision deadlines, accelerate some NCDs, and run annual reporting and billing investigations, all within limited appropriated resources.
- Device manufacturers — to qualify under the statute, some manufacturers (especially those using 510(k) pathways) will need to ensure clinical data include Medicare populations and prepare formal designation applications, creating additional development and regulatory costs.
- Providers facing audit risk — hospitals and suppliers may face more frequent CMS reviews for aberrant billing and will need stronger documentation showing use consistent with FDA labeling.
Key Issues
The Core Tension
The central dilemma is speed versus evidence: the statute prioritizes faster Medicare access to promising technologies by creating a time‑limited, label‑based coverage presumption, but doing so increases the risk that Medicare will pay for devices whose benefits and harms for typical Medicare patients are not yet well established — a tension between patient access and sound, evidence‑based stewardship of public funds.
The bill accelerates coverage but does so against a backdrop of uneven premarket evidence. Requiring clinical data that includes Medicare populations for 510(k) clearances narrows the evidence gap, but many devices cleared via 510(k) have smaller or less rigorous datasets than PMA devices.
Covering such products broadly for four years risks paying for interventions whose net benefit in an older, comorbid population remains uncertain. The statute tries to limit that risk by conditioning coverage on FDA labeling and allowing CMS to deny payment if it finds undue risk, but the operational threshold for an “undue risk” finding is not specified and could be difficult to apply consistently across device types.
Implementation challenges are numerous. CMS must coordinate timing between FDA priority review designations and its own six‑month clock; reconcile labeling language (which can be narrow) with clinical practice; and define what constitutes furnishing at the labeled frequency.
The $10 million per year provided is helpful but likely inadequate for sustained NCD workloads, surveillance, and provider audits if device uptake is rapid. The bill also leaves ambiguous how Medicare Advantage plans will treat breakthrough devices, potentially producing disparities between FFS and MA enrollees.
Finally, the authority to review aberrant billing is useful but may chill appropriate adoption if providers fear retrospective denial or heavy auditing.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.